An Open-Label, Randomized, Two-Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of Selpercatinib in Healthy Participants
Latest Information Update: 23 Mar 2025
At a glance
- Drugs Selpercatinib (Primary)
- Indications CNS cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Loxo Oncology
- 12 Jul 2022 Status changed from recruiting to completed.
- 10 May 2022 Status changed from not yet recruiting to recruiting.
- 15 Apr 2022 New trial record